Noriko Marutani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Noriko Marutani has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Kanta Yanagida
Health and Counseling Center Osaka University Osaka Japan
2 shared publications- Shoshin Akamine
Department of Psychiatry, Graduate School of Medicine, The University of Osaka, Suita, Osaka, Japan
2 shared publications - Takashi Kudo
Health and Counseling Center, Osaka University, Toyonaka, Japan
2 shared publications Aki Nagase
Department of Behavioral Neurology and Neuropsychiatry, United Graduate School of Child Development Osaka University Osaka Japan
1 shared publicationDaisuke Kanayama
Health and Counseling Center Osaka University Osaka Japan
1 shared publication- Daisuke Kanayama
Health and Counseling Center, Osaka University, Toyonaka, Japan
1 shared publication
Latest Publications
- 13 March 2022
- Published by Wiley in Psychogeriatrics
- Vol. 22 (3) , 353-359
Plasma NfL is associated with mild cognitive decline in patients with diabetes
Background: Patients with diabetes are at a higher risk for cognitive decline. Thus, biomarkers that can provide early and simple detection of cognitive decline are required. Neurofilament light chain (NfL) is a cytoskeletal protein that constitutes neural axons. Plasma NfL levels are elevated when neurodegeneration occurs. Here, we investigated whether plasma NfL levels were associated with cognitive decline in patients with type 2 diabetes.Method: This study included 183 patients with type 2 diabetes who visited Osaka University Hospital. All participants were tested for cognitive function using the Mini‐Mental State Examination (MMSE) and the Rivermead Behavioural Memory Test (RBMT). NfL levels were analysed in the plasma and the relationship between NfL and cognitive function was examined.Results: Lower RBMT‐standardized profile scores (SPS) or MMSE scores correlated with higher plasma NfL levels (one‐way analysis of variance: MMSE, P = 0.0237; RBMT‐SPS, P = 0.0001). Furthermore, plasma NfL levels (β = −0.34, P = 0.0005) and age (β = −0.19, P = 0.016) were significantly associated with the RBMT score after multivariable regression adjustment.Conclusions: Plasma NfL levels were correlated with mild cognitive decline which is detected by the RBMT but not the MMSE in patients with type 2 diabetes. This suggests that plasma NfL levels may provide a valuable clinical tool for identifying mild cognitive decline in patients with diabetes.
- 13 March 2022
- Published by Wiley in Psychogeriatrics
- Vol. 22 (3) , 353-359
Plasma NfL is associated with mild cognitive decline in patients with diabetes
Background: Patients with diabetes are at a higher risk for cognitive decline. Thus, biomarkers that can provide early and simple detection of cognitive decline are required. Neurofilament light chain (NfL) is a cytoskeletal protein that constitutes neural axons. Plasma NfL levels are elevated when neurodegeneration occurs. Here, we investigated whether plasma NfL levels were associated with cognitive decline in patients with type 2 diabetes.Method: This study included 183 patients with type 2 diabetes who visited Osaka University Hospital. All participants were tested for cognitive function using the Mini‐Mental State Examination (MMSE) and the Rivermead Behavioural Memory Test (RBMT). NfL levels were analysed in the plasma and the relationship between NfL and cognitive function was examined.Results: Lower RBMT‐standardized profile scores (SPS) or MMSE scores correlated with higher plasma NfL levels (one‐way analysis of variance: MMSE, P = 0.0237; RBMT‐SPS, P = 0.0001). Furthermore, plasma NfL levels (β = −0.34, P = 0.0005) and age (β = −0.19, P = 0.016) were significantly associated with the RBMT score after multivariable regression adjustment.Conclusions: Plasma NfL levels were correlated with mild cognitive decline which is detected by the RBMT but not the MMSE in patients with type 2 diabetes. This suggests that plasma NfL levels may provide a valuable clinical tool for identifying mild cognitive decline in patients with diabetes.
- Open Access
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S2)
Pathological significance of neuron‐derived EVs in Alzheimer's disease and their potential as biomarkers
Background: It has recently been reported that pathological molecules of Alzheimer’s disease (AD), such as tau, are transmitted through extracellular vesicles (EVs). We hypothesized that AD‐related proteins are detectable in neuron‐derived EVs (NDE) present in peripheral blood, since the pathological proteins will be protected by the lipid bilayer of EVs from degradation. The objective of the study is to assess the novel NDE isolation method for the quantification of AD‐related proteins using ultra‐sensitive digital ELISA method.Method: Blood‐derived EVs were first isolated from control and AD patients, and the degradation efficiency of AD‐related proteins in the blood and EVs was assessed by protease treatment in vitro. The remaining AD‐related molecules were quantified by Simoa HD‐1 Analyzer. The amount of protease‐resistant AD‐related proteins in the blood‐derived EVs was compared between healthy control subjects and AD patients. Next, NDE was affinity‐purified from peripheral blood‐derived EVs and conditioned medium of iPS‐derived neurons/astrocyte using novel antibodies specific to neuron‐specific membrane protein X (MPX). The purification efficiency was assessed by quantification of neuronal markers present in the isolated NDE.Result: Protease treatment of human plasma degraded more than 99% of Aβ40 and Aβ42 present in the blood. On the other hand, around 5% of tau in the blood was protease‐resistant implied that the 5% of tau in blood might be protected from proteases by the EV structure. Actually, in blood‐derived EV fraction, more than 50% of tau was protease resistant, although Aβ40 and Aβ42 were hardly detectable after protease treatment, indicated that 50% of EV‐associated tau was compartmentalized inside of the EV. Furthermore, we succeeded in efficient separation of NDE from blood‐derived EV fraction using anti‐MPX antibody.Conclusion: The present study revealed the difference in the amount of protease‐resistant Aβ40, Aβ42 and tau in the blood, which are more enriched in blood‐derived EVs. This phenomenon may be strongly involved in the transmission of AD pathological proteins through EVs. In addition, the novel NDE isolation method may be highly beneficial for the future development of NDE biomarkers.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S2)
Open AccessPathological significance of neuron‐derived EVs in Alzheimer's disease and their potential as biomarkers
Background: It has recently been reported that pathological molecules of Alzheimer’s disease (AD), such as tau, are transmitted through extracellular vesicles (EVs). We hypothesized that AD‐related proteins are detectable in neuron‐derived EVs (NDE) present in peripheral blood, since the pathological proteins will be protected by the lipid bilayer of EVs from degradation. The objective of the study is to assess the novel NDE isolation method for the quantification of AD‐related proteins using ultra‐sensitive digital ELISA method.Method: Blood‐derived EVs were first isolated from control and AD patients, and the degradation efficiency of AD‐related proteins in the blood and EVs was assessed by protease treatment in vitro. The remaining AD‐related molecules were quantified by Simoa HD‐1 Analyzer. The amount of protease‐resistant AD‐related proteins in the blood‐derived EVs was compared between healthy control subjects and AD patients. Next, NDE was affinity‐purified from peripheral blood‐derived EVs and conditioned medium of iPS‐derived neurons/astrocyte using novel antibodies specific to neuron‐specific membrane protein X (MPX). The purification efficiency was assessed by quantification of neuronal markers present in the isolated NDE.Result: Protease treatment of human plasma degraded more than 99% of Aβ40 and Aβ42 present in the blood. On the other hand, around 5% of tau in the blood was protease‐resistant implied that the 5% of tau in blood might be protected from proteases by the EV structure. Actually, in blood‐derived EV fraction, more than 50% of tau was protease resistant, although Aβ40 and Aβ42 were hardly detectable after protease treatment, indicated that 50% of EV‐associated tau was compartmentalized inside of the EV. Furthermore, we succeeded in efficient separation of NDE from blood‐derived EV fraction using anti‐MPX antibody.Conclusion: The present study revealed the difference in the amount of protease‐resistant Aβ40, Aβ42 and tau in the blood, which are more enriched in blood‐derived EVs. This phenomenon may be strongly involved in the transmission of AD pathological proteins through EVs. In addition, the novel NDE isolation method may be highly beneficial for the future development of NDE biomarkers.